Cargando…

LncRNA-NEF is downregulated in postmenopausal osteoporosis and is related to course of treatment and recurrence

OBJECTIVES: We investigated the role of long non-coding (lnc) RNA-NEF (neighboring enhancer of FoxA2), a characterized oncogene in cancer biology, in postmenopausal osteoporosis and its diagnostic and prognostic value in this disease. METHODS: Expression of lncRNA-NEF in plasma was detected by RNA e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaoyong, Guo, Zhixue, Gao, Wenshan, Wang, Jianzhong, Liu, Yong, Gao, Fei, Sun, Shaosong, Zhou, Xiaozhe, Yang, Zhaoyu, Zheng, Wenkui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683934/
https://www.ncbi.nlm.nih.gov/pubmed/31220986
http://dx.doi.org/10.1177/0300060519847854
Descripción
Sumario:OBJECTIVES: We investigated the role of long non-coding (lnc) RNA-NEF (neighboring enhancer of FoxA2), a characterized oncogene in cancer biology, in postmenopausal osteoporosis and its diagnostic and prognostic value in this disease. METHODS: Expression of lncRNA-NEF in plasma was detected by RNA extraction and real-time quantitative PCR. The diagnostic value of lncRNA-NEF and interleukin (IL)-6 for postmenopausal osteoporosis was evaluated by receiver operating characteristic curve analysis, with postmenopausal osteoporosis patients as true positive cases and healthy volunteers as true negative cases. RESULTS: We showed that plasma lncRNA-NEF was downregulated and plasma IL-6 was upregulated in postmenopausal osteoporosis patients compared with healthy controls. Altered plasma levels of lncRNA-NEF and IL-6 separated postmenopausal osteoporosis patients from healthy controls, and lncRNA-NEF and IL-6 were inversely and significantly correlated in osteoporosis patients. Patients were divided into high (n = 68) and low lncRNA-NEF (n = 73) groups according to Youden’s index. Patients with high lncRNA-NEF levels required a significantly shorter treatment course and had a lower post-treatment recurrence rate. CONCLUSION: We showed that lncRNA-NEF is downregulated in postmenopausal osteoporosis and is related to course of treatment and recurrence. The involvement of lncRNA-NEF in postmenopausal osteoporosis is likely related to IL-6.